New Discovery in the Prevention of Kidney Disease in Multiple Myeloma Patients
Posted: May 02, 2019
New Discovery in the Prevention of Kidney Disease in Multiple Myeloma Patients image
University of Alabama at Birmingham researchers have discovered a way to prevent kidney failure in multiple myeloma patients. 

Paul Sanders, MD, a nephrologist at UAB found that kidney damage can be prevented by blocking a pathway activated in the kidney by light chain proteins produced by the myeloma cells. 

The study was published in the Journal of Clinical Investigation. Essentially, free light chains that circulate have to be processed by the kidneys and can change kidney cell lining tissue biology.

These light chains are active proteins that can generate hydrogen peroxide - enough of it to activate a signaling pathway in a part of the kidney called the proximal tubule. Dr. Sanders said they identified a new intracellular signal mechanism called STAT1 (Signal transducer and activator of transcription 1) that was affected and caused inflammation. Says Sanders and colleagues: 

“To the extent that the experiments reflect the human condition, the studies offered new insights into the pathogenesis of progressive kidney failure that develops in the setting of multiple myeloma, which features increased circulating levels of monoclonal immunoglobulin fragments that require metabolism by the kidney. Targeting this pathway may prove beneficial in limiting the production of the FLCs and preventing the kidney injury that occurs from these proteins.”

Almost half of all patients with multiple myeloma also have kidney damage and about 8% need dialysis. This is an important discovery that could prevent such damage. 

“Even with modern chemotherapeutic options and extracorporeal therapies designed to target the removal of monoclonal FLCs, reductions in circulating FLCs require time, permitting progression of kidney disease, which may occur rapidly with persistently elevated serum FLC levels,” Sanders explained."

Currently, UAB researchers are working on developing molecules to block the pathway by which the light chains travel, which will eliminate kidney damage in people with multiple myeloma. Clinical trials will also be needed to demonstrate efficacy.

For more information, find the UAB research announcement here. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811